Overview

A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant

Status:
NOT_YET_RECRUITING

Trial end date:
2036-12-01

Target enrollment:

Participant gender:

Summary

This study is researching an experimental drug called linvoseltamab. The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are ineligible for autologous stem cell transplantation (transplant-ineligible). The main purpose of this study is to compare the effect and safety of linvoseltamab with the effect and safety of the standard treatment.

Phase:

PHASE3

Details

Lead Sponsor:

European Myeloma Network B.V.

Collaborator:

Regeneron Pharmaceuticals

Treatments:

daratumumab
Dexamethasone
Lenalidomide